A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemiaSaroj Vadhan‐Raj, Eric Roeland, Rafat Abonour et al.|Journal of Hematology & Oncology|2017Cited by 88
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumorsYonina R. Murciano‐Goroff, Joshua K. Sabari, Natraj Reddy Ammakkanavar et al.|Cancer Research|2023Cited by 37